BioTime

BioTime’s Cell Cure Files IND with FDA for ES cell AMD therapy

Cell-Cure-Logo

Stem cell biotech BioTime announced the news today that its subsidiary Cell Cure Neurosciences (Cell Cure) has filed an IND with the FDA for an embryonic stem (ES) cell-based therapy for Dry age-related macular degeneration (AMD). The product to be tested is OpRegen, which the company indicates is “the first IND for an ES cell-based …

BioTime’s Cell Cure Files IND with FDA for ES cell AMD therapy Read More »

TGIF stem cell headlines of week: Asterias, lasers, immunity, & more

Laser-tooth-stem-cells

It’s been an important week for stem cells. Although I’ve been busy working on multiple grants and papers, when I take a break I like to read up on what’s been going on with stem cells. What are the top stem cell stories and headlines of the week? CIRM awarded Asterias (a subsidiary of BioTime) …

TGIF stem cell headlines of week: Asterias, lasers, immunity, & more Read More »

Interview with BioTime CEO Michael West Part 1: a little stem cell history

Michael-West-PhD-CEO-of-BioTime-1-934x10241

It was my pleasure recently to  talk at length with Dr. Michael West, CEO of the Stem Cell Biotech, BioTime (BTX). West has been at the helm of BioTime since 2007 and is a true pioneer in the stem cell field. He founded Geron (GERN) and was a top leader at Advanced Cell Technology (ACT; stock …

Interview with BioTime CEO Michael West Part 1: a little stem cell history Read More »

A great day for stem cell research: more on SCOTUS & details on BioTime news

Today the Supreme Court announced it would not hear the Sherley v Sebelius case, ending the court battle that has left embryonic stem cell research (ESCR) in what I’ve called a “big chill”. This is great news. It is all over the mainstream media. Even the rampant anti-science, pro-lifers have declared defeat. I’m not going …

A great day for stem cell research: more on SCOTUS & details on BioTime news Read More »